Supernus Provides Regulatory Update for SPN-830
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- HPE raises networking revenue outlook, secures $1.2B Vultr order
Jefferies on Supernus (SUPN): 'We expect a -5-10% stock reaction after the FDA's rejection of SPN-830'
April 8, 2024 10:10 AM EDTJefferies analyst Irene Buhalo reiterated a Buy rating and $40.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN)
The analyst comments "We expect a -5-10% stock reaction after the FDA's rejection of SPN-830 (apomorphine pump) in Parkinson's. Street expectations were fairly low,... More
Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor'
April 8, 2024 10:09 AM EDTStifel analyst Annabel Samimy reiterated a Hold rating and $38.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN).
The analyst comments "SUPN announced that the resubmission review of SPN-830 (apomorphine infusion pump for PD) has been met with another CRL. Specifically, FDA is requesting additional... More
